Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies. 

In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of 30M cells and STK-009 doses ranging from 1.5-6mg, the combination therapy was well tolerated with no dose-limiting toxicities or IL-2-related toxicities observed.  

This regimen also demonstrated durable responses, including complete responses in all four patients with non-Hodgkin lymphoma (NHL).   

The data were presented by Dr Lia Palomba, Memorial Sloan Kettering Cancer Center, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. 

“Enhancing CAR-T cells with consistent cytokine support, particularly IL-2, has the potential to significantly improve their therapeutic effect. However, prolonged wild-type IL-2 administration is currently not feasible due to severe toxicities like capillary leak syndrome (CLS),” said Dr Palomba. “SYNCAR-001 + STK-009 represents an innovative solution, enabling the targeted delivery of a potent and durable IL-2 signal specifically to CAR-T cells in vivo and avoiding activation and proliferation of native lymphocytes that can cause CLS.” 

SYNCAR-001 + STK-009 is a cytokine-enabled cell therapy consisting of SYNCAR-001, an autologous CD19-targeting chimeric antigen receptor T (CAR-T) cell which expresses an engineered IL-2 receptor, and STK-009, an engineered pegylated IL-2 cytokine that selectively signals through the engineered IL-2 receptor.   

Debanjan Ray, Chief Executive Officer of Synthekine, said: “We are excited to report that STK-009 selectively delivered IL-2’s proliferation and activation signal to SYNCAR-001 cells without the toxicities, including CLS, that are typically associated with wild-type IL-2 treatment. Furthermore, the ability of STK-009 to provide an IL-2 signal exclusively to SYNCAR-001 cells may allow us to bypass the need for potentially toxic lymphodepleting chemotherapy (LDC).”

Diana Spencer, Senior Digital Content Editor, DDW